Active Biotech Management
Management criteria checks 3/4
Active Biotech's CEO is Helen Tuvesson, appointed in Jul 2017, has a tenure of 5.58 years. total yearly compensation is SEK4.41M, comprised of 46.4% salary and 53.6% bonuses, including company stock and options. directly owns 0.051% of the company’s shares, worth SEK128.49K. The average tenure of the management team and the board of directors is 5.6 years and 3.3 years respectively.
Key information
Helen Tuvesson
Chief executive officer
SEK 4.4m
Total compensation
| CEO salary percentage | 46.4% |
| CEO tenure | 5.6yrs |
| CEO ownership | 0.05% |
| Management average tenure | 5.6yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2022 | n/a | n/a | -SEK 58m |
| Sep 30 2022 | n/a | n/a | -SEK 60m |
| Jun 30 2022 | n/a | n/a | -SEK 57m |
| Mar 31 2022 | n/a | n/a | -SEK 54m |
| Dec 31 2021 | SEK 4m | SEK 2m | -SEK 50m |
| Sep 30 2021 | n/a | n/a | -SEK 38m |
| Jun 30 2021 | n/a | n/a | -SEK 35m |
| Mar 31 2021 | n/a | n/a | -SEK 32m |
| Dec 31 2020 | SEK 3m | SEK 2m | -SEK 32m |
| Sep 30 2020 | n/a | n/a | -SEK 39m |
| Jun 30 2020 | n/a | n/a | -SEK 40m |
| Mar 31 2020 | n/a | n/a | -SEK 36m |
| Dec 31 2019 | SEK 3m | SEK 2m | -SEK 34m |
| Sep 30 2019 | n/a | n/a | -SEK 32m |
| Jun 30 2019 | n/a | n/a | -SEK 31m |
| Mar 31 2019 | n/a | n/a | -SEK 35m |
| Dec 31 2018 | SEK 3m | SEK 1m | -SEK 37m |
| Sep 30 2018 | n/a | n/a | -SEK 88m |
| Jun 30 2018 | n/a | n/a | -SEK 88m |
| Mar 31 2018 | n/a | n/a | -SEK 103m |
| Dec 31 2017 | SEK 2m | SEK 1m | -SEK 109m |
Compensation vs Market: Helen's total compensation ($USD422.50K) is about average for companies of similar size in the UK market ($USD348.42K).
Compensation vs Earnings: Helen's compensation has increased whilst the company is unprofitable.
CEO
Helen Tuvesson (60 yo)
5.6yrs
Tenure
SEK 4,409,000
Compensation
Ms. Helen Tuvesson, Ph.D. is President of Active Biotech AB and its Chief Executive Officer since 2017. She serves as Independent Director at Mendus AB (publ) (formerly known as Immunicum AB (publ)) since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & CEO | 5.6yrs | SEK 4.41m | 0.051% SEK 128.5k | |
| Chief Financial Officer | 23.1yrs | no data | 0.057% SEK 143.2k | |
| Chief Medical Officer | 1.1yrs | no data | 0.017% SEK 42.2k |
5.6yrs
Average Tenure
Experienced Management: 0GQU's management team is seasoned and experienced (5.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 11.8yrs | SEK 209.00k | 1.36% SEK 3.4m | |
| Independent Director | 3.8yrs | SEK 203.00k | no data | |
| Independent Chairman of the Board | 3.8yrs | SEK 521.00k | 0.13% SEK 318.2k | |
| Independent Director | 2.8yrs | SEK 200.00k | no data | |
| Independent Director | 2.8yrs | SEK 205.00k | no data | |
| Independent Director | 2.8yrs | SEK 207.00k | 0.050% SEK 126.0k |
3.3yrs
Average Tenure
61.5yo
Average Age
Experienced Board: 0GQU's board of directors are considered experienced (3.3 years average tenure).